Oro-gastro-intestinal Digestion of Emulsified Fat
Obesity

About this trial
This is an interventional treatment trial for Obesity focused on measuring obesity, fat, appetite, digestion
Eligibility Criteria
Inclusion Criteria:
- Signed informed consent form
- Sex: male or female
- Age: 18-55 years
- Body Mass Index (BMI): 18-29 kg/m2
- Based on medical history and previous examination, no gastrointestinal complaints can be defined.
Exclusion Criteria:
- Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/-connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/-psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol
- Gastrointestinal or hepatic disorders influencing gastrointestinal absorption or transit
- Use of psychotropic drugs, including: benzodiazepines. Concomitant medication that can increase gastric pH (e.g. antacids, proton pump inhibitors, prostaglandins, anticholinergic agents, H2-receptor antagonists), or alter gastric emptying (e.g. metoclopramide, cisapride, domperidone and erythromycin, anticholinergics, tricyclic antidepressants, narcotic analgetics, adrenergic agents, calcium channel blockers), or alter intestinal transit (e.g., loperamide, chemical/osmotic/bulk laxatives) or influence satiety/energy intake (e.g. sibutramine, glucocorticoids, anabolic steroids), except oral contraceptives
- Pregnancy, lactation, wish to become pregnant during study, or having a positive pregnancy test at inclusion
- Reported unexplained weight loss/gain of more than 2 kg in the month before the study enrollment
- Score > 9 on Factor 1 (dietary restrained) of the Dutch translation of the Three Factor eating Questionnaire (TFEQ) [17]
- Blood donations less than three months previous to study enrollment, and for three months following participation
- One or more of the following dietary habits: medically prescribed diets, weight reduction diets, or vegetarian/macrobiotic/biologically dynamic food habits. Administration of investigational drugs in the 180 days prior to the study
- Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
- Premenstrual syndrome, dieting (medically prescribed, vegetarian, diabetic, biological dynamic)
- Excessive alcohol consumption (>20 alcoholic consumptions per week)
- Smoking
- Self-admitted HIV-positive state
Sites / Locations
- Maastricht University Medical Centre
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
emulsified fat, orally
intragastric administration of fat
intraduodenal administration of fat
intragastric, non-emulsified fat
At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically